After 1 day
+3.69%$24.41 → $25.31
Aug 13, 2026 → Aug 14, 2026
Alumis Inc. Common Stock
/ ALMSNMSWhat is ALMS stock?
ALMS is the U.S. stock ticker for Alumis Inc. Common Stock.
As of 2026-10-28: price $6.64; market cap $859.45M; latest earnings 2026-08-13; 12 recent 13F changes.
$6.64+2.00%
Yahoo Finance ↗·Updated 10/28/2026, 12:21 PM UTC
- Current price
- $6.64
- Market cap
- $859.45M
- Latest earnings date
- Aug 13, 2026
- Data status
- Current
Yahoo Finance
Polygon.io
Nasdaq
Price change after earnings
After 7 days
-6.35%$24.41 → $22.86
Aug 13, 2026 → Aug 20, 2026
After 30 days
-62.23%$24.41 → $9.22
Aug 13, 2026 → Sep 14, 2026
Before-market or after-market timing is unavailable.
Reported date confirmed
Recent insider transactions
| Date | Trader / role | Type | Shares | Average price | Transaction value | Source |
|---|---|---|---|---|---|---|
| Sep 08, 2026 | AKKARAJU SRINIVAS director | Sold | 48,065 | $10.55 | $507.01K | SEC ↗ |
| Sep 08, 2026 | AKKARAJU SRINIVAS director | Purchased | 273,291 | $10.63 | $2.9M | SEC ↗ |
| Sep 08, 2026 | AKKARAJU SRINIVAS director | Purchased | 273,290 | $10.63 | $2.9M | SEC ↗ |
| Sep 08, 2026 | AKKARAJU SRINIVAS director | Sold | 48,066 | $10.55 | $507.02K | SEC ↗ |
| Sep 04, 2026 | AKKARAJU SRINIVAS director | Purchased | 220,070 | $11.17 | $2.46M | SEC ↗ |
| Sep 04, 2026 | AKKARAJU SRINIVAS director | Purchased | 220,070 | $11.17 | $2.46M | SEC ↗ |
| Aug 03, 2026 | Bradley Mark Christopher Chief Development Officer | Sold | 2,572 | $26.37 | $67.82K | SEC ↗ |
| Aug 03, 2026 | Hardiman Roy C. Chief Business & Strategy Ofcr | Sold | 2,692 | $26.37 | $70.99K | SEC ↗ |
| Aug 03, 2026 | Schroer John R. Chief Financial Officer | Sold | 3,282 | $26.37 | $86.55K | SEC ↗ |
| Aug 03, 2026 | Goldstein David M Chief Scientific Officer | Sold | 2,596 | $26.37 | $68.46K | SEC ↗ |
| Aug 03, 2026 | Drappa Jorn Chief Medical Officer | Sold | 2,447 | $26.37 | $64.53K | SEC ↗ |
| Aug 03, 2026 | Pangali Sanam Chief Legal Officer | Sold | 1,364 | $26.37 | $35.97K | SEC ↗ |
director
48,065 · $10.55 · $507.01K
Sep 08, 2026SEC Form 4 ↗
AKKARAJU SRINIVASPurchased
director
273,291 · $10.63 · $2.9M
Sep 08, 2026SEC Form 4 ↗
AKKARAJU SRINIVASPurchased
director
273,290 · $10.63 · $2.9M
Sep 08, 2026SEC Form 4 ↗
director
48,066 · $10.55 · $507.02K
Sep 08, 2026SEC Form 4 ↗
AKKARAJU SRINIVASPurchased
director
220,070 · $11.17 · $2.46M
Sep 04, 2026SEC Form 4 ↗
AKKARAJU SRINIVASPurchased
director
220,070 · $11.17 · $2.46M
Sep 04, 2026SEC Form 4 ↗
Chief Development Officer
2,572 · $26.37 · $67.82K
Aug 03, 2026SEC Form 4 ↗
Hardiman Roy C.Sold
Chief Business & Strategy Ofcr
2,692 · $26.37 · $70.99K
Aug 03, 2026SEC Form 4 ↗
Schroer John R.Sold
Chief Financial Officer
3,282 · $26.37 · $86.55K
Aug 03, 2026SEC Form 4 ↗
Chief Scientific Officer
2,596 · $26.37 · $68.46K
Aug 03, 2026SEC Form 4 ↗
Drappa JornSold
Chief Medical Officer
2,447 · $26.37 · $64.53K
Aug 03, 2026SEC Form 4 ↗
Pangali SanamSold
Chief Legal Officer
1,364 · $26.37 · $35.97K
Aug 03, 2026SEC Form 4 ↗
Updated: 09/10/2026, 05:35 AM UTC
13F institutional changes
| Quarter | Institution | Type | Shares held | Share change | Value change | Source |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | BlackRock, Inc. | Added | 8,218,151 | +1,047,283 | +$73.28M | SEC 13F ↗ |
| Jun 30, 2026 | FMR LLC / Fidelity | Added | 6,769,170 | +5,795,388 | +$169.03M | SEC 13F ↗ |
| Jun 30, 2026 | Vanguard Capital Management LLC | Added | 4,215,703 | +183,437 | +$29.8M | SEC 13F ↗ |
| Mar 31, 2026 | UBS Group AG | Added | 3,054,865 | +2,940,869 | +$64.79M | SEC 13F ↗ |
| Jun 30, 2026 | State Street Corp | Added | 2,187,266 | +385,454 | +$21.86M | SEC 13F ↗ |
| Jun 30, 2026 | Geode Capital Management, LLC | Added | 2,168,517 | +250,102 | +$18.76M | SEC 13F ↗ |
| Mar 31, 2026 | Janus Henderson Group PLC | Added | 2,124,408 | +29,331 | +$646.02K | SEC 13F ↗ |
| Mar 31, 2026 | Invesco Ltd. | Added | 1,511,537 | +1,089,673 | +$24.01M | SEC 13F ↗ |
| Jun 30, 2026 | JPMorgan Chase & Co. | New position | 969,617 | +108,042 | +$8.99M | SEC 13F ↗ |
| Jun 30, 2026 | Vanguard Portfolio Management LLC | Added | 921,211 | +208,603 | +$10.22M | SEC 13F ↗ |
| Mar 31, 2026 | Marshall Wace, LLP | Added | 1,172,749 | +799,856 | +$17.62M | SEC 13F ↗ |
| Mar 31, 2026 | Goldman Sachs Group Inc. | Added | 718,040 | +290,889 | +$6.41M | SEC 13F ↗ |
BlackRock, Inc.Added
- Quarter
- Jun 30, 2026
- Shares held
- 8,218,151
- Share change
- +1,047,283
- Value change
- +$73.28M
FMR LLC / FidelityAdded
- Quarter
- Jun 30, 2026
- Shares held
- 6,769,170
- Share change
- +5,795,388
- Value change
- +$169.03M
- Quarter
- Jun 30, 2026
- Shares held
- 4,215,703
- Share change
- +183,437
- Value change
- +$29.8M
UBS Group AGAdded
- Quarter
- Mar 31, 2026
- Shares held
- 3,054,865
- Share change
- +2,940,869
- Value change
- +$64.79M
State Street CorpAdded
- Quarter
- Jun 30, 2026
- Shares held
- 2,187,266
- Share change
- +385,454
- Value change
- +$21.86M
- Quarter
- Jun 30, 2026
- Shares held
- 2,168,517
- Share change
- +250,102
- Value change
- +$18.76M
- Quarter
- Mar 31, 2026
- Shares held
- 2,124,408
- Share change
- +29,331
- Value change
- +$646.02K
Invesco Ltd.Added
- Quarter
- Mar 31, 2026
- Shares held
- 1,511,537
- Share change
- +1,089,673
- Value change
- +$24.01M
JPMorgan Chase & Co.New position
- Quarter
- Jun 30, 2026
- Shares held
- 969,617
- Share change
- +108,042
- Value change
- +$8.99M
- Quarter
- Jun 30, 2026
- Shares held
- 921,211
- Share change
- +208,603
- Value change
- +$10.22M
Marshall Wace, LLPAdded
- Quarter
- Mar 31, 2026
- Shares held
- 1,172,749
- Share change
- +799,856
- Value change
- +$17.62M
- Quarter
- Mar 31, 2026
- Shares held
- 718,040
- Share change
- +290,889
- Value change
- +$6.41M
Share counts are derived from reported value divided by the filing price and are rounded for display.
Key people timeline
- Martin Babler
Envudeucitinib’s Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23/IL-17-driven diseases, and our anticipated Phase 2b LUMUS readout in SLE may substantiate its role in IFN-driven diseases -- potentially unlocking broader potential of our TYK2 franchise
Alumis Inc. Common Stock (ALMS) - Martin Babler
Alumis delivered a focused and productive first quarter, building on the Phase 3 clinical validation of envudeucitinib in moderate - to - severe plaque psoriasis and reinforcing the differentiated potential of maximal TYK2 inhibition
Alumis Inc. Common Stock (ALMS)
Related data
Data sources and methodology
Prices use Yahoo Finance, earnings dates use Nasdaq, and company reference data prefers Polygon.io. When Polygon market cap is unavailable, the page derives it from the latest SEC shares outstanding multiplied by the Yahoo price. Insider and institutional records link to SEC EDGAR, and missing values are never invented.
Updated: 10/28/2026, 12:21 PM UTC
Collection, calculation and correction policy- Yahoo Finance
- 10/28/2026, 12:21 PM UTC
- Polygon.io
- 10/28/2026, 12:21 PM UTC
- Nasdaq earnings history
- 08/13/2026, 12:00 AM UTC
- SEC Form 4
- 09/10/2026, 05:35 AM UTC
- SEC 13F
- 08/07/2026, 05:05 PM UTC
- Statements / public records
- 08/13/2026, 08:20 PM UTC